Osteoporosis and Injection site cellulitis

Summary:

Injection site cellulitis is found among people with Osteoporosis, especially for people who are female, 60+ old.

The study analyzes which people have Injection site cellulitis with Osteoporosis. It is created by eHealthMe based on reports of 28 people who have Osteoporosis from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

What is Osteoporosis?

Osteoporosis (bones weak and more likely to break) is found to be associated with 1,806 drugs and 1,905 conditions by eHealthMe. Check the latest studies of Osteoporosis.

What is Injection site cellulitis?

Injection site cellulitis (injection site inflammation) is found to be associated with 166 drugs and 307 conditions by eHealthMe. Check the latest studies of Injection site cellulitis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 28, 2026

28 people who have Osteoporosis and Injection Site Cellulitis are studied.

Would you have Injection site cellulitis when you have Osteoporosis?

Gender of people who have Osteoporosis and experienced Injection Site Cellulitis *:

female: 89.29 %
male: 10.71 %

Age of people who have Osteoporosis and experienced Injection Site Cellulitis *:

Common co-existing conditions for these people *:

Depression: 6 people, 21.43%
Inflammation: 4 people, 14.29%
Stress And Anxiety: 4 people, 14.29%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 4 people, 14.29%
Pain: 4 people, 14.29%
Gastric Disorder (disease of stomach): 4 people, 14.29%
High Blood Pressure: 4 people, 14.29%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 3 people, 10.71%
Cancer Pain: 2 people, 7.14%
Breast Cancer: 2 people, 7.14%

Common drugs taken by these people *:

Common symptoms for these people *:

Pain: 6 people, 21.43%
Intracranial Haematoma (intracranial localized swelling filled with blood): 4 people, 14.29%
Hepatic Enzyme Increased: 4 people, 14.29%
Femur Fracture: 4 people, 14.29%
Impaired Healing: 4 people, 14.29%
Urinary Tract Infection: 4 people, 14.29%
Injection Site Infection: 4 people, 14.29%
Injection Site Inflammation: 4 people, 14.29%
Diabetic Ulcer: 4 people, 14.29%
Large Intestinal Ulcer: 4 people, 14.29%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Injection site cellulitis?

- Check whether Injection site cellulitis is associated with a drug or a condition

Related publications that referenced our studies

Hirschmann S, Gibel A, Tsvelikhovsky I, Lisker A, "Late-Onset Psychosis and Risedronate Treatment for Osteoporosis: A Case Report", Clinical schizophrenia & related psychoses, 2013 May .
Ko KD, Cho BL, "Risedronate-related Localized Amnesia in an Elderly Patient with Osteoporosis", Journal of the Korean Geriatrics Society, 2012 Dec .
Lee WY, Sun LM, Lin MC, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH, "A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study", PloS one, 2012 Dec .
Hirschmann S, Gibel A, Tsvelikhovsky I, Lisker A, "Late-Onset Psychosis and Risedronate Treatment for Osteoporosis: A Case Report", Clinical schizophrenia & related psychoses, 2013 May .
Ko KD, Cho BL, "Risedronate-related Localized Amnesia in an Elderly Patient with Osteoporosis", Journal of the Korean Geriatrics Society, 2012 Dec .
Lee WY, Sun LM, Lin MC, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH, "A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study", PloS one, 2012 Dec .

Related studies:

How the study uses the data?

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

The study is based on Injection site cellulitis and Osteoporosis, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.